Healx lands $56m to power artificial intelligence-led drug discovery
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
Storm clouds gather for biotech flotations
Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Japanese drugmakers stand out at the nine-month mark
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Europe and Asia provide a safe haven as US stocks falter
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
A new reality for Immunocore
A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
The contrasting fortunes of Envista and Smiledirectclub
Two dental companies go public inside a week, with very different results.
With new unicorn status, CMR Surgical sets profitability target
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.